Contact Us

Yes. CBS rescue experiments are well-established for homocystinuria research: • Construct design: use a codon-modified CBS sequence with a small C-terminal tag (FLAG, HA). CBS has N-terminal heme-binding regulatory domain (CBS is uniquely heme-regulated), central PLP-binding catalytic domain, and C-terminal Bateman/CBS domain (SAM allosteric regulation) — preserve all elements. • Catalytically-dead rescue: PLP-binding lysine mutations abolish catalytic activity. • Patient mutation rescue: I278T (pyridoxine-responsive, most common variant), G307S (pyridoxine-non-responsive) for classical homocystinuria modeling — these variants distinguish therapy-responsive vs unresponsive patients. • Functional readout: rescue should restore homocysteine clearance and cystathionine production. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying CASP8's role as the initiator caspase of the extrinsic apoptosis pathway in non-tumor hepatocyte context. The Knockout line is the standard tool for asking whether CASP8 is required for these processes — CASP8 is activated by death receptor (FAS, TRAIL-R, TNFR1) signaling through the DISC (death-inducing signaling complex) containing FADD; CASP8 cleaves and activates downstream executioner caspases (CASP3, CASP7) and BID (linking extrinsic to intrinsic apoptosis); critically, CASP8 also suppresses RIPK1/RIPK3-mediated necroptosis — CASP8 loss switches death receptor signaling from apoptosis to necroptosis. Overexpression is useful for studying CASP8 in heterologous expression contexts. For non-tumor hepatocyte CASP8 research, the EDITGENE CASP8 Knockout in L-02 enables study of CASP8 biology in hepatic context — hepatocytes are particularly susceptible to apoptosis-necroptosis switching in liver injury and inflammatory conditions. This product complements the parallel CASP8 Knockouts in A-549 (lung cancer) and A-375 (BRAF V600E melanoma) for systematic cross-background validation. Rescue with wild-type, catalytically-dead (C360S), or DED-deficient CASP8 enables structure-function studies. The knockout is valuable for studying apoptosis-necroptosis switching in liver injury, hepatic inflammation, and emerging RIPK1 kinase inhibitor (necrostatin-1s, GSK2982772) research.

Yes. CASP8 rescue experiments are well-established for apoptosis-necroptosis research: • Construct design: use a codon-modified CASP8 sequence with a small C-terminal tag (FLAG, HA). CASP8 has two N-terminal DED (death effector domain) domains and C-terminal protease domain with catalytic C360 — preserve all elements. • Catalytically-dead rescue: C360S mutation in the catalytic cysteine abolishes proteolytic activity but retains DISC binding — this rescue restores necroptosis suppression scaffolding function while preventing apoptosis. • DED-deficient rescue: DED domain mutations disrupt FADD/DISC assembly. • Functional readout: rescue should restore death receptor-induced apoptosis and necroptosis suppression. L-02-specific considerations: • L-02 is a human hepatocyte cell line widely used in Chinese hepatology research as a non-tumorigenic normal liver model — provides a complementary non-cancer hepatocyte context to HCC lines (Hep-G2, Huh-7) and hepatoblastoma (HuH-6). • Lentiviral transduction is supported with moderate efficiency. • Recent authentication studies have identified some L-02 stocks as HeLa-derived; users should authenticate their L-02 line and complement findings in other hepatocyte models.

The choice depends on whether you are studying CNR1 (cannabinoid receptor 1, CB1)'s role as the principal CNS cannabinoid receptor or modeling its functions in glioblastoma and cannabinoid pharmacology. The Knockout line is the standard tool for asking whether CB1 is required for these processes — CNR1 is a Gαi/o-coupled seven-transmembrane GPCR activated by endocannabinoids (anandamide/AEA, 2-arachidonoylglycerol/2-AG) and exocannabinoids (Δ⁹-THC, synthetic cannabinoids), with the highest CNS GPCR expression and roles in synaptic plasticity, pain, appetite, anxiety, and energy metabolism. Overexpression is useful for studying CB1 in heterologous expression contexts. For neuro-oncology and cannabinoid pharmacology research, the EDITGENE CNR1 Knockout in U251 MG is uniquely valuable — U251 MG is a glioblastoma cell line, and CB1 has been characterized in glioblastoma biology with reported antitumor effects of cannabinoid agonists; cannabinoid therapy has been explored for GBM. CNR2 (CB2) paralog expression analysis aids interpretation. Rescue with wild-type or signaling-deficient CB1 enables structure-function studies. The knockout is a critical specificity tool for ⭐ rimonabant (Acomplia, withdrawn anti-obesity CB1 inverse agonist due to depression/suicide risks), Δ⁹-THC, nabilone, dronabinol (FDA-approved cannabinoids for chemotherapy-induced nausea, AIDS-related anorexia), and emerging CB1-targeted therapeutics.

Yes. CB1 rescue experiments are well-established for cannabinoid pharmacology research: • Construct design: use a codon-modified CNR1 sequence with a small intracellular C-terminal tag (FLAG, HA). CB1 is a seven-transmembrane GPCR with N-terminal extracellular region, transmembrane bundle, and C-terminal intracellular tail — preserve all elements; note that C-terminal tags may affect β-arrestin recruitment. • Surface localization validation: confirm plasma membrane localization before cannabinoid binding studies. • Signaling-deficient rescue: DRY motif mutations disrupt Gαi/o coupling. • Biased agonism studies: specific mutations can generate G-protein-biased or β-arrestin-biased CB1 variants. • Functional readout: rescue should restore cannabinoid-induced cAMP suppression and ERK activation. U251 MG-specific considerations: • U251 MG is a human glioblastoma multiforme (GBM) cell line — one of the principal continuous GBM models for neuro-oncology, BBB research, and cannabinoid pharmacology in glial-derived cancer context. • Lentiviral transduction is supported with moderate efficiency. • U251 MG retains key GBM features and is widely used for studying brain tumor biology and CNS pharmacology.

The choice depends on whether you are studying ATRX (α-thalassemia/mental retardation syndrome X-linked)'s role as a chromatin remodeler and H3.3 chaperone or modeling its functions in alternative lengthening of telomeres (ALT) and emerging cancer applications. The Knockout line is the standard tool for asking whether ATRX is required for these processes — ATRX is a SWI/SNF-family chromatin remodeling ATPase that, together with the histone chaperone DAXX, deposits H3.3 at heterochromatin (telomeres, pericentromeres, and other repeats); ATRX maintains telomere stability and represses ALT-mediated telomere maintenance, with critical roles in heterochromatin biology. Overexpression is useful for studying ATRX in heterologous expression contexts. For cancer biology research, the EDITGENE ATRX Knockout in HEK293T is uniquely valuable — HEK293T supports systematic structure-function studies of this large multifunctional protein. ATRX mutations cause ⭐ ATR-X syndrome (X-linked intellectual disability with α-thalassemia, hypogenitalism, characteristic facies); ATRX loss-of-function mutations are characteristic of ⭐⭐ adult diffuse gliomas (especially IDH-mutant astrocytomas) and pancreatic neuroendocrine tumors (panNETs), where ATRX loss enables ALT for telomere maintenance. Rescue with wild-type or ATPase-dead ATRX enables structure-function studies. The knockout is valuable for studying ALT biology, ATR-X syndrome modeling, and emerging ALT-pathway-targeted cancer therapeutics.

Yes, with technical considerations for this large multi-domain protein: • Construct design: use a codon-modified ATRX sequence with a small C-terminal tag (FLAG, HA). ATRX is a ~280 kDa protein with N-terminal ADD (ATRX-DNMT3-DNMT3L) domain and C-terminal SNF2 ATPase domain — full-length rescue is technically challenging due to ~7.5 kb mRNA size. • Domain-focused rescue: ADD or SNF2 domain-focused constructs may be more tractable for specific functional rescue. • ATPase-dead rescue: K1538I in the Walker A motif abolishes ATPase/chromatin remodeling activity. • DAXX partnership: rescue interpretation considers DAXX expression for H3.3 deposition. • Functional readout: rescue should restore ALT suppression and proper H3.3 deposition at telomeres/heterochromatin. HEK293T transduces with very high efficiency and supports stable rescue line generation.

The choice depends on whether you are studying ATF4 (activating transcription factor 4)'s role as the master integrated stress response (ISR) transcription factor or modeling its functions in skin stress and emerging cancer applications. The Knockout line is the standard tool for asking whether ATF4 is required for these processes — ATF4 is a bZIP transcription factor uniquely regulated at the translational level: upstream ORFs (uORFs) in the 5'UTR allow selective ATF4 translation during ISR-induced eIF2α phosphorylation (PERK, GCN2, PKR, HRI kinases respond to ER stress, amino acid starvation, dsRNA, heme deficiency); ATF4 drives expression of amino acid biosynthesis, autophagy, and pro-apoptotic genes including CHOP. Overexpression is useful for studying ATF4 gain-of-function effects. For skin and ISR research, the EDITGENE ATF4 Knockout in HaCaT is highly relevant — HaCaT is a human keratinocyte line, and ATF4-ISR is critical for skin stress responses. Rescue with wild-type or DNA-binding-deficient ATF4 enables structure-function studies. The knockout is valuable for studying integrated stress response biology, amino acid stress responses, and emerging ATF4-targeted approaches including ISR modulators (ISRIB, GCN2 inhibitors) and ATF4 PROTACs in cancer drug development.

Yes. ATF4 rescue experiments require attention to the bZIP architecture and unique uORF translation control: • Construct design: use a codon-modified ATF4 ORF only (without 5'UTR uORFs) with a small C-terminal tag (FLAG, HA) — including ATF4's natural 5'UTR uORFs preserves ISR-induced translational control but constitutive expression requires uORF removal. • DNA-binding-deficient rescue: basic region mutations abolish CRE/ARE element binding. • Dimerization-deficient rescue: leucine zipper mutations disrupt bZIP dimerization with C/EBP partners. • Functional readout: rescue should restore ATF4 target gene (CHOP, ASNS, GADD34) induction during ISR. HaCaT-specific considerations: • HaCaT is a spontaneously immortalized human keratinocyte cell line — the principal continuous keratinocyte model for skin biology, UV response, and dermatological research. • Lentiviral transduction is supported with moderate efficiency. • HaCaT retains keratinocyte features and is widely used for studying epidermal stress responses including ATF4-driven integrated stress response (ISR).

The choice depends on the experimental question. CECR2 (cat eye syndrome chromosome region candidate 2) is a chromatin remodeler component with characterized roles in neural tube closure and DNA damage response. The Knockout line is appropriate for asking whether CECR2 is required for predicted activities — CECR2 is a BRD (bromodomain)-containing protein that forms the CERF chromatin remodeling complex (CECR2-containing remodeling factor) with SNF2H/SMARCA5; CERF has been implicated in neural tube closure (exencephaly in Cecr2 mutant mice) and DNA damage response. Overexpression is useful for studying CECR2 in heterologous expression contexts. For chromatin remodeling research, the EDITGENE CECR2 Knockout in HAP1 provides a clean genetic background for characterizing CECR2-specific functions. Rescue with wild-type or bromodomain-mutant CECR2 enables structure-function studies. The knockout is valuable for studying ISWI-family chromatin remodeling, CERF complex function, and emerging bromodomain inhibitor specificity (BRD inhibitors with CECR2 selectivity are in development).

Yes. CECR2 rescue experiments require attention to bromodomain reader architecture: • Construct design: use a codon-modified CECR2 sequence with a small C-terminal tag (FLAG, HA). CECR2 has DDT (DNA-binding homeobox and Different Transcription factors) domain, BRD (bromodomain), and SANT-like domain — preserve all elements. • Bromodomain-mutant rescue: N514F or analogous Asn-to-Phe mutations in the BRD acetyl-lysine binding pocket abolish acetyl-mark recognition. • SNF2H/SMARCA5 partnership: rescue interpretation considers SNF2H expression for CERF complex assembly. • Functional readout: rescue should restore CERF complex chromatin remodeling activity. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying ATAD2 (ATPase family AAA domain containing 2)'s role as a bromodomain-containing AAA+ ATPase or modeling its emerging functions as a cancer target. The Knockout line is the standard tool for asking whether ATAD2 is required for these processes — ATAD2 is an unusual protein combining AAA+ ATPase domain and a bromodomain (acetyl-lysine reader), with reported roles as a histone chaperone-like activity, MYC coactivator, and oncogenic driver; ATAD2 is overexpressed in many cancers and correlates with poor prognosis. Overexpression is useful for studying ATAD2 gain-of-function effects. For cancer drug development research, the EDITGENE ATAD2 Knockout in HAP1 provides a clean genetic background for characterizing ATAD2-specific functions. Rescue with wild-type, ATPase-dead, or bromodomain-mutant ATAD2 enables structure-function studies. The knockout is a critical specificity tool for emerging ATAD2-selective bromodomain inhibitors (GSK8814, BAY-850, AT19) in cancer drug development — ATAD2 has been characterized as a promising 'undruggable' cancer target now accessible through chemical biology approaches.

Yes. ATAD2 rescue experiments are uniquely useful for the dual-domain architecture: • Construct design: use a codon-modified ATAD2 sequence with a small C-terminal tag (FLAG, HA). ATAD2 has central AAA+ ATPase domain and C-terminal bromodomain — preserve all elements. • ATPase-dead rescue: Walker A or Walker B motif mutations abolish ATPase activity. • Bromodomain-mutant rescue: N1064F asparagine mutation in the acetyl-lysine binding pocket abolishes acetyl-mark recognition. • Functional readout: rescue should restore ATAD2-dependent phenotypes; bromodomain-mutant rescue tests the specific contribution of acetyl-mark reading. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying BRD2's role as a BET (bromodomain and extra-terminal) family chromatin reader or modeling BET inhibitor pharmacology. The Knockout line is the standard tool for asking whether BRD2 is required for these processes — BRD2 is a member of the BET family (BRD2, BRD3, BRD4, BRDT) that recognizes acetyl-lysine marks on histone tails and transcription factors through tandem bromodomains; BET proteins recruit P-TEFb to active enhancers and drive transcriptional elongation, with critical roles in MYC and other oncogene expression. Overexpression is useful for studying BRD2 in heterologous expression contexts. Important consideration: BET family (BRD2, BRD3, BRD4) members share substantial substrate scope — single BRD2 knockout may show modest phenotypes if BRD3/BRD4 compensate. Rescue with wild-type or bromodomain-mutant BRD2 (N156A/N429A in BD1/BD2 asparagine of acetyl-lysine binding pocket) is the standard specificity control. The knockout is a critical specificity tool for pan-BET inhibitors (JQ1, OTX015/birabresib, molibresib/iBET-762, mivebresib, pelabresib) and BD1- or BD2-selective BET inhibitors (RVX-208/apabetalone for BD2-selective) in cancer drug development; also relevant for emerging BET-targeted PROTACs (ARV-771, dBET1).

Yes. BRD2 rescue experiments are well-established for BET inhibitor research: • Construct design: use a codon-modified BRD2 sequence with a small C-terminal tag (FLAG, HA). BRD2 has two bromodomains (BD1, BD2) and extra-terminal (ET) domain — preserve all elements. • Bromodomain-mutant rescue: N156A (BD1) and N429A (BD2) asparagine mutations in the acetyl-lysine binding pocket abolish acetyl-mark recognition — useful for BD-selective inhibitor research. • ET-domain-mutant rescue: ET domain mutations disrupt P-TEFb recruitment. • Functional readout: rescue should restore acetyl-histone-dependent chromatin recruitment. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.